The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Cadavid Diego since 2020.
The trader's CIK number is 1778713.
At the time of the last reporting, Cadavid Diego was the SVP Clinical Development of Fulcrum Therapeutics, Inc.. (stock ticker symbol FULC).
Also see all insider trading activities at Fulcrum Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | FULC | 0 | $0 | 10,937 | $206,409 | 5,580 | $26,947 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-07-01 | FULC | Sale | 1,071 | 18.30 | 19,599 |
| 2020-06-25 | FULC | Option Ex | 1,459 | 4.83 | 7,046 |
| 2020-06-25 | FULC | Sale | 1,459 | 22.00 | 32,098 |
| 2020-06-10 | FULC | Sale | 401 | 22.00 | 8,822 |
| 2020-06-10 | FULC | Option Ex | 401 | 4.83 | 1,936 |
| 2020-06-05 | FULC | Sale | 451 | 20.18 | 9,100 |
| 2020-06-04 | FULC | Sale | 226 | 20.05 | 4,531 |
| 2020-06-05 | FULC | Option Ex | 451 | 4.83 | 2,178 |
| 2020-06-04 | FULC | Option Ex | 226 | 4.83 | 1,091 |
| 2020-06-02 | FULC | Option Ex | 45 | 4.83 | 217 |
| 2020-06-03 | FULC | Option Ex | 338 | 4.83 | 1,632 |
| 2020-06-02 | FULC | Sale | 45 | 20.00 | 900 |
| 2020-06-03 | FULC | Sale | 338 | 20.18 | 6,819 |
| 2020-05-29 | FULC | Sale | 200 | 20.04 | 4,007 |
| 2020-05-28 | FULC | Sale | 600 | 20.00 | 12,000 |
| 2020-05-29 | FULC | Option Ex | 200 | 4.83 | 966 |
| 2020-05-28 | FULC | Option Ex | 600 | 4.83 | 2,898 |
| 2020-05-12 | FULC | Option Ex | 1,860 | 4.83 | 8,983 |
| 2020-05-12 | FULC | Sale | 1,860 | 18.00 | 33,480 |
| 2020-03-02 | FULC | Sale | 2,143 | 17.69 | 37,911 |
| 2020-02-03 | FULC | Sale | 2,143 | 17.33 | 37,142 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Cadavid Diego (SVP Clinical Development of Fulcrum Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.